Aden K.Y. Chan

Dr. Aden K.Y. Chan


Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2017 in Journal of Clinical Oncology
Verified
Journal Article
Closed access
ALAlvaro Lassaletta
Alvaro Lassaletta
MZMichal Zapotocky
Michal Zapotocky
MMMatthew Mistry
Matthew Mistry
Vijay RamaswamyVijay Ramaswamy
Vijay Ramaswamy
MHMarion Honnorat
Marion Honnorat
UTUri Tabori
Uri Tabori
Purpose: BRAF V600E is a potentially highly targetable mutation detected in a subset of pediatric low-grade gliomas (PLGGs). Its biologic and clinical effect within this diverse group of tumors remains unknown. Patients and Methods: A combined clinical and genetic institutional study of patients with PLGGs with long-term follow-up was performed (N = 510). Clinical and treatment data of patients with BRAF V600E mutated PLGG (n = 99) were compared with a large international independent cohort of patients with BRAF V600E mutated-PLGG (n = 180). Results: BRAF V600E mutation was detected in 69 of 405 patients (17%) with PLGG across a broad spectrum of histologies and sites, including midline locations, which are not often routinely biopsied in clinical practice. Patients with BRAF V600E PLGG exhibited poor outcomes after chemotherapy and radiation therapies that resulted in a 10-year progression-free survival of 27% (95% CI, 12.1% to 41.9%) and 60.2% (95% CI, 53.3% to 67.1%) for BRAF V600E and wild-type PLGG, respectively ( P < .001). Additional multivariable clinical and molecular stratification revealed that the extent of resection and CDKN2A deletion contributed independently to poor outcome in BRAF V600E PLGG. A similar independent role for CDKN2A and resection on outcome were observed in the independent cohort. Quantitative imaging analysis revealed progressive disease and a lack of response to conventional chemotherapy in most patients with BRAF V600E PLGG. Conclusion: BRAF V600E PLGG constitutes a distinct entity with poor prognosis when treated with current adjuvant therapy.

27 May 2017 in Neuro-Oncology
Verified
Journal Article
Closed access
PDF file
AAAbudumijit Aibaidula
Abudumijit Aibaidula
ACAden K.Y. Chan
Aden K.Y. Chan
ZSZhifeng Shi
Zhifeng Shi
YLYanxi Li
Yanxi Li
RZRuiqi Zhang
Ruiqi Zhang
HNHo-Keung NG
Ho-Keung NG
Astrocytoma of the isocitrate dehydrogenase (IDH) wild-type gene is described as a provisional entity within the new World Health Organization (WHO) classification. Some groups believe that IDH wild-type lower-grade gliomas, when interrogated for other biomarkers, will mostly turn out to be glioblastoma. We hypothesize that not all IDH wild-type lower-grade gliomas have very poor outcomes and the group could be substratified prognostically. Seven hundred and eighteen adult WHO grades II and III patients with gliomas from our hospitals were re-reviewed and tested for IDH1/2 mutations. One hundred and sixty-six patients with IDH wild-type cases were identified for further studies, and EGFR and MYB amplifications, mutations of histone H3F3A, TERT promoter (TERTp), and BRAF were examined. EGFR amplification, BRAF, and H3F3A mutations were observed in 13.8%, 6.9%, and 9.5% of patients, respectively, in a mutually exclusive pattern in IDH wild-type lower-grade gliomas. TERTp mutations were detected in 26.8% of cases. Favorable outcome was observed in patients with young age, oligodendroglial phenotype, and grade II histology. Independent adverse prognostic values of older age, nontotal resection, grade III histology, EGFR amplification, and H3F3A mutation were confirmed by multivariable analysis. Tumors were further classified into “molecularly” high grade (harboring EGFR, H3F3A, or TERTp) (median overall survival = 1.23 y) and lower grade (lacking all of the 3) (median overall survival = 7.63 y) with independent prognostic relevance. The most favorable survival was noted in molecularly lower-grade gliomas with MYB amplification. Adult IDH wild-type lower-grade gliomas are prognostically heterogeneous and do not have uniformly poor prognosis. Clinical information and additional markers, including MYB, EGFR, TERTp, and H3F3A, should be examined to delineate discrete favorable and unfavorable prognostic groups.

1 February 2015 in Laboratory Investigation
Verified
Journal Article
Closed access
ACAden K.Y. Chan
Aden K.Y. Chan
YYYu Yao
Yu Yao
ZZZhenyu Zhang
Zhenyu Zhang
NCNellie Yuk-Fei Chung
Nellie Yuk-Fei Chung
JLJoseph Shu-Ming Liu
Joseph Shu-Ming Liu
HNHo-Keung Ng
Ho-Keung Ng

6 January 2023 in Science Advances
Verified
Journal Article
Closed access
LYLei Yu
Lei Yu
XWXinlei Wang
Xinlei Wang
QMQuanhua Mu
Quanhua Mu
STSindy Sing Ting Tam
Sindy Sing Ting Tam
DLDanson Shek Chun Loi
Danson Shek Chun Loi
AWAngela Wu
Angela Wu
Single-cell multi-omics can provide a unique perspective on tumor cellular heterogeneity. Most previous single-cell whole-genome RNA sequencing (scWGS-RNA-seq) methods demonstrate utility with intact cells from fresh samples. Among them, many are not applicable to frozen samples that cannot produce intact single-cell suspensions. We have developed scONE-seq, a versatile scWGS-RNA-seq method that amplifies single-cell DNA and RNA without separating them from each other and hence is compatible with frozen biobanked samples. We benchmarked scONE-seq against existing methods using fresh and frozen samples to demonstrate its performance in various aspects. We identified a unique transcriptionally normal-like tumor clone by analyzing a 2-year frozen astrocytoma sample, demonstrating that performing single-cell multi-omics interrogation on biobanked tissue by scONE-seq could enable previously unidentified discoveries in tumor biology.

17 December 2012 in Brain Pathology
Verified
Journal Article
Closed access
PDF file
KLKay Ka‐Wai Li
Kay Ka‐Wai Li
LYLing Yang
Ling Yang
JPJesse Chung‐Sean Pang
Jesse Chung‐Sean Pang
ACAden K.Y. Chan
Aden K.Y. Chan
LZLiangfu Zhou
Liangfu Zhou
HNHo-Keung NG
Ho-Keung NG

1 March 2014 in Laboratory Investigation
Verified
Journal Article
Closed access
PDF file
ACAden K.Y. Chan
Aden K.Y. Chan
JPJesse Chung-Sean Pang
Jesse Chung-Sean Pang
NCNellie Yuk-Fei Chung
Nellie Yuk-Fei Chung
KLKay Ka-Wai Li
Kay Ka-Wai Li
WPWai Sang Poon
Wai Sang Poon
HNHo-Keung Ng
Ho-Keung Ng